US stocks: Summit shares drop after US FDA declines to approve lung cancer drug
Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials. Despite Summit's emphasis on regional survival differences, analysts worry that this decision could have repercussions for similar treatments in development. Investors now eagerly await new trial results comparing ivonescimab with conventional lung cancer therapies.
Key Takeaways
- Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials.
- Despite Summit's emphasis on regional survival differences, analysts worry that this decision could have repercussions for similar treatments in development.
- Investors now eagerly await new trial results comparing ivonescimab with conventional lung cancer therapies.
Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials. Despite Summit's emphasis on regional survival differences, analysts worry that this decision could have repercussions for similar treatments in development. Investors now eagerly await new trial results comparing ivonescimab with conventional lung cancer therapies.
Original Publisher Attribution
This summary was curated from Economic Times.